EPS is indicated in patients with syncope and previous myocardial infarction, or other scar-related conditions when syncope remains unexplained after non-invasive evaluation. |
|
69
|
EPS may be considered in patients with syncope and asymptomatic sinus bradycardia, in a few instances when non-invasive tests (e.g. ECG monitoring) have failed to show a correlation between syncope and bradycardia |
|
70–72
|
EPS may be considered in patients with EF ≤ 40%, without a primary prophylactic ICD indication, and non-sustained VT in ICM (MUSTT criteria) to ascertain the presence of sustained VT events. |
|
73
|
EPS may be helpful in patients with syncope and presence of a cardiac scar, including those with a previous myocardial infarction, or other scar-related conditions, when the mechanism of syncope remains unexplained after non-invasive evaluation. |
|
66
,
70
,
71
,
73
|
EPS may be considered in patients with syncope and bifascicular block, when the mechanism of syncope remains unexplained after non-invasive evaluation. |
|
67
,
70
,
71
,
74
|
EPS may be considered for risk stratification of SCD in patients with tetralogy of Fallot who have one or more risk factors among LV dysfunction, non-sustained VT and QRS duration exceeding 180 ms. |
|
67
,
70
,
71
,
74
|
EPS may be considered in patients with congenital heart disease and non-sustained VT to determine the risk of sustained VT or identify SVT that could be ablate. |
|
67
,
70
,
71
,
74
|
EPS may be considered in asymptomatic patients with spontaneous type 1 Brugada ECG pattern, or drug-induced type 1 ECG pattern and additional risk factors. |
|
75–77
|
EPS is not recommended for additional risk stratification in patients with either long or short QT, catecholaminergic VT or early repolarization. |
|
70
,
71
|
EPS is not recommended for risk stratification in patients with ischaemic or non-ischaemic DCM who meet criteria for ICD implantation. |
|
70
,
71
|